S&P Futures
3,320.25+4.25(+0.13%)Dow Futures
27,112.00+57.00(+0.21%)Nasdaq Futures
11,093.25+1.50(+0.01%)
Calithera Biosciences, Inc. (CALA)
5.11 +0.03 (0.59%)
After hours: 4:15PM EDT
Chart Events
Performance Outlook
| Previous Close | 5.00 |
| Open | 5.04 |
| Bid | 5.02 x 1400 |
| Ask | 5.09 x 800 |
| Day's Range | 4.98 - 5.14 |
| 52 Week Range | 2.45 - 8.18 |
| Volume | 422,497 |
| Avg. Volume | 710,851 |
| Market Cap | 357.855M |
| Beta (5Y Monthly) | 2.21 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.69 |
| Earnings Date | Aug 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.50 |
- GlobeNewswire
Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the compensation committee of the company’s board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 30,000 shares of Calithera’s common stock, at a per share exercise price of $4.70, the closing trading price on July 31, 2020. One-fourth of the option vests in July 2021, and the balance of the option vests in a series of thirty-six successive equal monthly installments thereafter and was granted pursuant to the Calithera Biosciences, Inc. 2018 Inducement Plan, or Inducement Plan, which was approved by Calithera’s board of directors in January 2018 in accordance with Nasdaq Listing Rule 5653(c)(4). The stock option also has a ten year term and are subject to the terms and conditions of the Inducement Plan and the stock option agreement pursuant to which the option was granted. The stock options were granted as an inducement material to the new employees entering into employment with Calithera in accordance with Nasdaq Listing Rule 5635(c)(4).About CalitheraCalithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.Forward Looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the safety, tolerability and efficacy of Calithera’s product candidates, the overall advancement of Calithera’s product candidates in clinical trials, the unmet need in the treatment of patients with advanced disease, and Calithera’s plans to continue development of its product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, and other periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.SOURCE: Calithera Biosciences, Inc. CONTACT:Jennifer McNealey ir@Calithera.com 650-870-1071
- GlobeNewswire
Calithera Biosciences to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020
SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Company’s second quarter 2020 financial results will be released on Monday, August 10, 2020. Company management will host a conference call on Monday, August 10, 2020 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.calithera.com. The conference call can be accessed by dialing (855) 783-2599 (domestic) or (631) 485-4877 (international) and refer to conference ID 4562868. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for replay on Calithera’s website for 30 days.About CalitheraCalithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially starve tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.Forward Looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the safety, tolerability and efficacy of Calithera’s product candidates, the overall advancement of Calithera’s product candidates in clinical trials, the unmet need in the treatment of patients with advanced disease, and Calithera’s plans to continue development of its product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, and other periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.SOURCE: Calithera Biosciences, Incorporated CONTACT: Jennifer McNealey ir@Calithera.com 650-870-1071
- GlobeNewswire
Calithera Biosciences Appoints Scott Garland to Board of Directors
Former Portola Pharmaceuticals President and Chief Executive Officer Brings Extensive Executive Leadership and Commercial Oncology ExperienceSOUTH SAN FRANCISCO, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences announced today the appointment of Scott Garland to its board of directors. Garland is a 29-year veteran of the biopharmaceutical industry who most recently served as the president and chief executive officer of recently-acquired Portola Pharmaceuticals. “Scott’s exceptional executive leadership and commercial expertise, as well as his deep background in oncology, make him an ideal and timely addition to the Calithera board,” said Susan Molineaux, PhD, president and chief executive officer of Calithera. “We are excited to have his perspective as we move telaglenastat closer to market and continue to advance our pipeline.”In his most recent role as president and chief executive officer of Portola Pharmaceuticals, Garland led the company through the commercial launch of Andexxa® and a successful acquisition by biopharmaceutical company Alexion. Garland served concurrently as a board member for Karyopharm Therapeutics. Before joining Portola, Garland held multiple marketing and sales roles at leading pharmaceutical and biotechnology companies. At Relypsa, he served first as chief commercial officer, then as president overseeing the U.S. commercial launch of Veltassa® for the treatment of hyperkalemia. Prior to Relypsa, Garland spent three years as chief commercial officer at Exelixis where he led the launch of cabozantinib in medullary thyroid cancer and over nine years at Genentech, including five years as a vice president and national sales director. At Genentech, Mr. Garland led the commercial franchises for two multi-billion dollar therapies – Avastin® and Rituxan®.“I am impressed by Calithera’s robust pipeline and approach, as well as the scientific rigor employed by the company,” said Garland. “It is an honor to join their board, particularly as they continue to expand their clinical program and approach several significant clinical milestones.”Garland received a Bachelor of Science degree from California Polytechnic State University-San Luis Obispo and a master’s degree in Business Administration from the Fuqua School of Business at Duke University.About CalitheraCalithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.Forward Looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the safety, tolerability and efficacy of Calithera’s product candidates, the overall advancement of Calithera’s product candidates in clinical trials, the unmet need in the treatment of patients with advanced disease, and Calithera’s plans to continue development of its product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, and other periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.SOURCE: Calithera Biosciences, Inc.CONTACTS:Investor Relations Jennifer McNealey Calithera ir@Calithera.com 650-870-1071Media Michele Parisi Sam Brown, Inc. micheleparisi@sambrown.com 925-864-5028
